334970 — Prestige Biologics Co Balance Sheet
0.000.00%
- KR₩246bn
- KR₩334bn
- KR₩13bn
Annual balance sheet for Prestige Biologics Co, fiscal year end - June 30th, KRW millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 36,775 | 15,383 | 45,435 | 29,507 | 1,582 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 8,252 | 2,077 | 2,073 | 1,654 | 4,963 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 54,860 | 29,835 | 70,242 | 55,636 | 40,848 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 149,989 | 227,107 | 234,435 | 233,052 | 228,406 |
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 206,768 | 258,079 | 305,753 | 289,414 | 270,286 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 28,393 | 32,552 | 89,098 | 92,306 | 102,417 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 99,936 | 140,468 | 205,950 | 217,732 | 135,083 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| ESOP Debt Guarantee | |||||
| Other Equity | |||||
| Total Equity | 106,832 | 117,611 | 99,803 | 71,682 | 135,203 |
| Total Liabilities & Shareholders' Equity | 206,768 | 258,079 | 305,753 | 289,414 | 270,286 |
| Total Common Shares Outstanding |